X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SHASUN PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SHASUN PHARMA SANOFI INDIA/
SHASUN PHARMA
 
P/E (TTM) x 38.9 123.9 31.4% View Chart
P/BV x 7.3 8.5 85.9% View Chart
Dividend Yield % 0.5 0.2 222.3%  

Financials

 SANOFI INDIA   SHASUN PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
SHASUN PHARMA
Mar-14
SANOFI INDIA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4,94594 5,249.5%   
Low Rs3,90146 8,554.8%   
Sales per share (Unadj.) Rs1,081.8214.2 505.1%  
Earnings per share (Unadj.) Rs141.65.3 2,652.9%  
Cash flow per share (Unadj.) Rs185.915.8 1,175.3%  
Dividends per share (Unadj.) Rs33.001.00 3,300.0%  
Dividend yield (eoy) %0.71.4 52.2%  
Book value per share (Unadj.) Rs868.853.3 1,628.7%  
Shares outstanding (eoy) m23.0356.62 40.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.3 1,252.8%   
Avg P/E ratio x31.213.1 238.5%  
P/CF ratio (eoy) x23.84.4 538.4%  
Price / Book Value ratio x5.11.3 388.5%  
Dividend payout %23.318.7 124.4%   
Avg Mkt Cap Rs m101,8623,958 2,573.7%   
No. of employees `0003.2NA-   
Total wages/salary Rs m3,6852,164 170.3%   
Avg. sales/employee Rs Th7,691.9NM-  
Avg. wages/employee Rs Th1,137.7NM-  
Avg. net profit/employee Rs Th1,006.5NM-  
INCOME DATA
Net Sales Rs m24,91412,127 205.4%  
Other income Rs m807229 351.9%   
Total revenues Rs m25,72112,356 208.2%   
Gross profit Rs m5,3721,009 532.4%  
Depreciation Rs m1,022594 172.2%   
Interest Rs m11415 2.6%   
Profit before tax Rs m5,146230 2,240.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,886-73 -2,593.5%   
Profit after tax Rs m3,260302 1,079.0%  
Gross profit margin %21.68.3 259.1%  
Effective tax rate %36.6-31.7 -115.8%   
Net profit margin %13.12.5 525.2%  
BALANCE SHEET DATA
Current assets Rs m14,4326,884 209.6%   
Current liabilities Rs m6,0108,456 71.1%   
Net working cap to sales %33.8-13.0 -260.8%  
Current ratio x2.40.8 295.0%  
Inventory Days Days6162 98.8%  
Debtors Days Days28108 26.5%  
Net fixed assets Rs m7,9914,970 160.8%   
Share capital Rs m230113 203.3%   
"Free" reserves Rs m19,7782,875 688.0%   
Net worth Rs m20,0083,020 662.5%   
Long term debt Rs m01,817 0.0%   
Total assets Rs m27,77013,347 208.1%  
Interest coverage x468.81.6 30,180.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.9 98.7%   
Return on assets %11.85.4 219.2%  
Return on equity %16.310.0 162.9%  
Return on capital %25.813.3 193.5%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m6,3065,843 107.9%   
Fx outflow Rs m5,2572,173 241.9%   
Net fx Rs m1,0493,669 28.6%   
CASH FLOW
From Operations Rs m4,351398 1,094.3%  
From Investments Rs m-787-1,635 48.1%  
From Financial Activity Rs m-1,8841,309 -144.0%  
Net Cashflow Rs m1,68071 2,359.6%  

Share Holding

Indian Promoters % 0.0 39.2 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 3.6 400.0%  
FIIs % 14.6 17.6 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 39.6 26.5%  
Shareholders   15,184 20,750 73.2%  
Pledged promoter(s) holding % 0.0 12.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; IT & Energy Stocks Gain(Closing)

Indian share markets traded on a volatile note throughout the day and ended their session on a flat note. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

TORRENT PHARMA at All Time High; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Jan 16, 2019 | Updated on Jan 16, 2019

TORRENT PHARMA share price has hit an all time high at Rs 1,914 (up 1.1%). The BSE HEALTHCARE Index is up by 0.1%. Among the top gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 1.1%) and SANOFI INDIA (up 0.8%). The top losers include ABBOTT INDIA and AUROBINDO PHARMA (down 0.1%).

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

15 Mistakes to Avoid to Make a Killing in the Markets(Profit Hunter)

Jan 3, 2019

Richa dissects the common mistakes investors make and how to avoid and even take advantage of them.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 16, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS